Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3.

Buart S, Terry S, Noman MZ, Lanoy E, Boutros C, Fogel P, Dessen P, Meurice G, Gaston-Mathé Y, Vielh P, Roy S, Routier E, Marty V, Ferlicot S, Legrès L, Bouchtaoui ME, Kamsu-Kom N, Muret J, Deutsch E, Eggermont A, Soria JC, Robert C, Chouaib S.

Oncotarget. 2017 Oct 30;8(65):108786-108801. doi: 10.18632/oncotarget.22150. eCollection 2017 Dec 12.

2.

A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents.

Azan A, Caspers PJ, Bakker Schut TC, Roy S, Boutros C, Mateus C, Routier E, Besse B, Planchard D, Seck A, Kamsu Kom N, Tomasic G, Koljenović S, Noordhoek Hegt V, Texier M, Lanoy E, Eggermont AM, Paci A, Robert C, Puppels GJ, Mir LM.

Cancer Res. 2017 Jan 15;77(2):557-565. doi: 10.1158/0008-5472.CAN-16-1733. Epub 2016 Nov 11.

3.

Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines.

Malka-Mahieu H, Girault I, Rubington M, Leriche M, Welsch C, Kamsu-Kom N, Zhao Q, Desaubry L, Vagner S, Robert C.

Cell Cycle. 2016 Sep 16;15(18):2405-9. doi: 10.1080/15384101.2016.1208862. Epub 2016 Aug 11.

4.

Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy.

Dercle L, Ammari S, Champiat S, Massard C, Ferté C, Taihi L, Seban RD, Aspeslagh S, Mahjoubi L, Kamsu-Kom N, Robert C, Marabelle A, Schlumberger M, Soria JC, Postel-Vinay S.

Eur J Cancer. 2016 Sep;65:33-42. doi: 10.1016/j.ejca.2016.05.031. Epub 2016 Jul 21.

PMID:
27451022
5.

Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF-CRAF Heterodimerization.

Boussemart L, Girault I, Malka-Mahieu H, Mateus C, Routier E, Rubington M, Kamsu-Kom N, Thomas M, Tomasic G, Agoussi S, Breckler M, Laporte M, Lacroix L, Eggermont AM, Cavalcanti A, Grange F, Adam J, Vagner S, Robert C.

Cancer Res. 2016 Mar 15;76(6):1476-84. doi: 10.1158/0008-5472.CAN-15-2900-T. Epub 2016 Jan 29.

6.

eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.

Boussemart L, Malka-Mahieu H, Girault I, Allard D, Hemmingsson O, Tomasic G, Thomas M, Basmadjian C, Ribeiro N, Thuaud F, Mateus C, Routier E, Kamsu-Kom N, Agoussi S, Eggermont AM, Désaubry L, Robert C, Vagner S.

Nature. 2014 Sep 4;513(7516):105-9. doi: 10.1038/nature13572. Epub 2014 Jul 27.

PMID:
25079330
7.

Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients.

Boussemart L, Routier E, Mateus C, Opletalova K, Sebille G, Kamsu-Kom N, Thomas M, Vagner S, Favre M, Tomasic G, Wechsler J, Lacroix L, Robert C.

Ann Oncol. 2013 Jun;24(6):1691-7. doi: 10.1093/annonc/mdt015. Epub 2013 Feb 13.

PMID:
23406731
8.

Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.

Arnault JP, Mateus C, Escudier B, Tomasic G, Wechsler J, Hollville E, Soria JC, Malka D, Sarasin A, Larcher M, André J, Kamsu-Kom N, Boussemart L, Lacroix L, Spatz A, Eggermont AM, Druillennec S, Vagner S, Eychène A, Dumaz N, Robert C.

Clin Cancer Res. 2012 Jan 1;18(1):263-72. doi: 10.1158/1078-0432.CCR-11-1344. Epub 2011 Nov 17.

9.

EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies.

Poindessous V, Ouaret D, El Ouadrani K, Battistella A, Mégalophonos VF, Kamsu-Kom N, Petitprez A, Escargueil AE, Boudou P, Dumont S, Cervera P, Fléjou JF, André T, Tournigand C, Chibaudel B, de Gramont A, Larsen AK.

Clin Cancer Res. 2011 Oct 15;17(20):6522-30. doi: 10.1158/1078-0432.CCR-11-1607. Epub 2011 Aug 31.

10.

Supplemental Content

Loading ...
Support Center